Debbie Hay

Deborah Lucy Hay FRSNZ is a New Zealand academic.[1] In 2022, she was elected a Fellow of the Royal Society Te Apārangi.

Debbie Hay

FRSNZ
Born
Deborah Lucy Hay
Alma materImperial College London
Scientific career
Fieldsmolecular pharmacology
Institutions
Thesis

Academic career

After an undergraduate in pharmacology at the University of Sheffield, Hay did a PhD in molecular pharmacology entitled 'Investigation of the calcitonin receptor-like receptor and receptor activity modifying proteins' at Imperial College London. Hay moved to the University of Auckland, where she rose to full professor. She is now a full professor at the University of Otago and is a Fellow of the British Pharmacological Society.

Her research involves molecular pharmacological techniques[2] to investigate phenomenon such as migraines.[3][4]

In 2022, Hay was elected a Fellow of the Royal Society Te Apārangi. The society said "Professor Debbie Hay is an innovative molecular pharmacologist whose seminal contributions have enhanced understanding of the roles of G protein-coupled receptors (GPCRs) in conditions such as migraine, diabetes and obesity... ...she has established herself as a world leader in a complex field, in high demand internationally as a collaborator, speaker, writer and consultant to industry."[5]

Selected works
  • Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, Whiting L, Phillips AR, Hay DL. "Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes." Br J Pharmacol 2012 May;166(1):151-67.
  • Bailey RJ, Hay DL. "Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor." Br J Pharmacol. 2007 Jul;151(5):678-87.
  • Dakin, C. L., I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, M. A. Ghatei, and S. R. Bloom. "Oxyntomodulin inhibits food intake in the rat." Endocrinology 142, no. 10 (2001): 4244–4250.
  • Hay, Debbie L., David R. Poyner, and Patrick M. Sexton. "GPCR modulation by RAMPs." Pharmacology & Therapeutics 109, no. 1 (2006): 173–197.
  • Hay, Debbie L., George Christopoulos, Arthur Christopoulos, David R. Poyner, and Patrick M. Sexton. "Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes." Molecular Pharmacology 67, no. 5 (2005): 1655–1665.
  • Hay, Debbie L., Stephen G. Howitt, Alex C. Conner, Marcus Schindler, David M. Smith, and David R. Poyner. "CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22–52, CGRP8–37 and BIBN4096BS." British Journal of Pharmacology 140, no. 3 (2003): 477–486.
  • Walker, Christopher S., Alex C. Conner, David R. Poyner, and Debbie L. Hay. "Regulation of signal transduction by calcitonin gene-related peptide receptors." Trends in Pharmacological Sciences 31, no. 10 (2010): 476–483.

References
  1. "Professor Debbie Hay - The University of Auckland". Unidirectory.auckland.ac.nz. Retrieved 4 January 2018.
  2. "University of Auckland celebrates Marsden fund success | Scoop News". Scoop.co.nz. 3 November 2016. Retrieved 4 January 2018.
  3. "Pain relief: New Zealand's breakthrough in migraine treatment". The New Zealand Herald. 9 March 2015. Retrieved 4 January 2018.
  4. Ceinwen Curtis - ceinwen.curtis@radionz.co.nz (10 April 2015). "Research offers migraine treatment hope | Radio New Zealand News". Radionz.co.nz. Retrieved 4 January 2018.
  5. "Researchers and scholars at the top of their fields elected as Fellows". Royal Society Te Apārangi. Retrieved 18 March 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.